ClinicalTrials.gg
RecruitingNCT07301749EXPANDUpdated Jun 22, 2026

A Clinical Study Evaluating the Safety and Efficacy of the VCFix Spinal System for Treatment of Vertebral Compression Fractures

An interventional study of VCFix Spinal System in stand-alone configuration in Vertebral Compression Fracture, sponsored by Amber Implants B.V.. Recruiting at 3 sites in 2 countries. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Amber Implants B.V. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Non-randomized
Ages
21 Years to 85 Years
Sex
All
01

Study summary

This study is being conducted to evaluate the safety and performance of the VCFix Spinal System, a medical device designed to treat certain types of spinal fractures called vertebral compression fractures (VCFs) in adults.

Up to 8 hospitals in Europe will take part in the study. All participants will receive treatment with the VCFix device. The treatment will be provided according to the intended use of the device and may be performed either with or without the use of a special bone cement.

Participants will be assigned to one of two study groups before treatment:

Cementless group: the VCFix device is implanted without bone cement. Cemented group: the VCFix device is implanted together with bone cement.

The study will assess how well the treatment works and how safe it is. Researchers will evaluate:

Changes in back pain 6 months after treatment compared with before treatment. Changes in daily functioning and ability to perform everyday activities 6 months after treatment compared with before treatment.

Whether any serious device-related complications occur during the first month after treatment.

The results will help determine whether treatment with the VCFix device provides benefits for patients with vertebral compression fractures while maintaining an acceptable safety profile.

02

Conditions studied

  • Vertebral Compression Fracture

Keywords

  • VCF
  • EXPAND
  • vertebral stabilization
  • fracture
  • trauma
  • osteoporosis
  • expandable implant
03

In context

Fractures, Bone

723 studies on the registry are indexed under Fractures, Bone; 114 are open to participants now.

This study's planned enrollment of 148 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Amber Implants B.V. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥ 21 to ≤ 85 years old.
  2. Single vertebral fracture which meets all of the following criteria:

    • Type A fractures from AO spine classification (compression injuries);
    • Vertebral fracture located in the thoracic and lumbar regions of the spine
    • Fracture age \< 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
    • Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
    • Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery
  3. Subject has a NPRS back pain score of ≥5
  4. Subject is a candidate for surgical intervention based on investigator opinion
  5. Subject has a (BMI) \< 35
  6. Subject is mentally capable of complying with trial protocol requirements for the duration of the study
  7. Subject can understand the risks and benefits of participating in the study and is able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
  2. Non-mobile fractures (i.e., fracture is not recent (>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).
  3. Spondylolisthesis > Grade 1 at target vertebral body(s)
  4. Local kyphotic angle > 30°
  5. Pre-existing vertebral fracture prior to the index fracture
  6. Subjects that require anterior stabilization of the index fracture
  7. Fracture to the pedicle based on radiographic evaluation
  8. Spinal cord compression or canal compromise requiring decompression
  9. Severe back pain due to causes other than acute fracture with NPRS score>5
  10. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
  11. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication
  12. Pre-existing neurological deficit, radiculopathy or myelopathy
  13. Pre-existing condition or significant co-morbidity:

    • Uncontrolled diabetes ( >8%)
    • Severe cardiopulmonary deficiencies
    • Any other condition that would impact study outcome in the opinion of the investigator
  14. to both MRI and radionuclide bone scan
  15. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study.
  16. A less than the study duration or undergoing palliative care
  17. Subject non-ambulatory prior to fracture
  18. Allergy to any components of the device/instruments used during the procedure
  19. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
  20. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)
  21. Any evidence of alcohol or drug abuse.
  22. Ongoing long-term therapy (steroid dose ≥30 mg /day for >3 months)
  23. The subject is currently on anti-cancer therapy or anti- therapy
  24. Pregnancy or subjects with that are unwilling to use throughout the study duration
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Cemented cohort

    Implant of the VCFix device with the use of PMMA bone cement

    Device: VCFix Spinal System in stand-alone configuration

  • Experimental
    Uncemented cohort

    Implant of the VCFix device without the use of PMMA bone cement

    Device: VCFix Spinal System in stand-alone configuration

Interventions

  • DeviceVCFix Spinal System in stand-alone configuration

    The distinguishing features of this inetrvention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to likely secure and reinforce the vertebra without using PMMA bone cement, avoiding all the symptomatic and asymptomatic side effects of bone cement. 4. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

06

What researchers measure

Primary outcomes

  1. Reduction of more than 2 points in vertebral fracture-related pain intensity at 6 months after the index procedure compared to baseline as measured by a 11-point Numerical Pain Rating Scale (NPRS)

    Time frame: 6 months

  2. Maintenance or improvement of function as measured by the 100-point Oswestry Disability Index (ODI) at 6 months compared to baseline

    Time frame: 6 months

  3. Absence of serious adverse device effects (SADEs): No SADEs with causality rated as definite, monitored through 1 month post-procedure (safety)

    Time frame: 1 month

Secondary outcomes

  1. Vertebral height restoration (anterior, midline, and posterior aspects) at PO (Post-Operative), 1Months FU, 6 Months FU and 12Months FU.

    Time frame: Post-Operative, 1Month FU, 6 Months FU, 12 Months FU

  2. Kyphotic angle and Cobb angle improvement at Post-Operative, 1 Month FU, 6 Months FU and 12 Months FU.

    Kyphotic angle and Cobb angle improvement

    Time frame: Post-Operative, ost-Operative, 1 Month FU, 6 Months FU and 12 Months FU.

  3. Reduction in vertebral fracture-related pain (measured by the 11-point Numerical Pain Rating Scale (NPRS))

    Reduction in vertebral fracture-related pain

    Time frame: Discharge, 1, 3, 6 and 12 Months FU compared to baseline.

  4. Improvement in function (measured by the 100-point Oswestry Disability Index (ODI)) at discharge, 1, 3, 6 and 12 months FU compared to baseline.

    Time frame: Discharge, 1, 3, 6 and 12 months FU

  5. Improvement of Health-related quality of life (HRQoL) measured by EuroQol 5-Dimension Scale (EQ-5D-5L) at 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline

    Improvement of Health-related quality of life (HRQoL)

    Time frame: 1 Month, 3 Months, 6 Months and 12 Months post-procedure compared to baseline

  6. Device-related serious adverse events assessed at 12- and 24- months post-procedure.

    Device-related serious adverse events

    Time frame: 12 months FU, 24 months FU

  7. All (per protocol reportable) adverse events assessed at 12- and 24- months post-procedure.

    Time frame: 12 Months FU, 24 Months FU

07

Study locations

2 of 3 sites recruiting
  • Centre Hospitalier Métropole de Savoie
    Chambéry, France
    Not yet recruiting
  • Wilhelmsburger Krankenhaus Groß-Sand
    Hamburg, Germany
    Recruiting
  • Krankenhaus Mechernich
    Mechernich, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301749
Lead sponsor
Amber Implants B.V.
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Nov 4, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Clinical Research Manager
Contact
expand@amberimplants.com
+31 15 200 2151

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion